Leerink Partners raised its price target on Zimmer Biomet (NYSE: ZBH) to $146.00 (from $142.00) while maintaining a Outperform rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Zimmer Biomet (ZBH) PT Raised to $138 at Baird on 4Q Report; 'Revenues Shows Signs of Stabilization'January 31, 2018 8:18 AM Stifel Upgrades Zimmer Biomet (ZBH) to BuyJanuary 31, 2018 4:21 AM Zimmer Biomet (ZBH) PT Raised to $155 at Needham & CompanyJanuary 30, 2018 1:11 PM Zimmer Biomet Holdings (ZBH) Reports In-Line Q4 EPS; Guides Q1 Modestly Below the StreetJanuary 30, 2018 7:02 AM Zimmer Biomet Announces Fourth Quarter and Full-Year 2017 ResultsJanuary 30, 2018 7:00 AM